Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
Address
86 Morris Avenue
SUMMIT, NJ 07901
United States
Key stats and ratios
|
| Net profit margin | 26.28% | 26.44% |
| Operating margin | 31.67% | 31.71% |
| EBITD margin | - | 39.93% |
| Return on average assets | 13.32% | 13.40% |
| Return on average equity | 27.45% | 25.99% |
| Employees | 4,700 |
** June 17, 2013 charts : daily, weekly, monthly **
No comments:
Post a Comment